Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 12, 2000, Pages 3381-3388

  Roberts, J ^a   Schock, K ^a   Marino, S ^a   Andriole, V T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; FUNGUS ANTIGEN; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RABBIT; SURVIVAL TIME;

ANIMALS; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BRAIN; DISEASE MODELS, ANIMAL; LIVER; LUNG; PEPTIDES, CYCLIC; RABBITS; THIAZOLES; TRIAZOLES;

EID: 0034425534     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.12.3381-3388.2000     Document Type: Article

References (28)

1. Aspergillus infections: Problems in diagnosis and treatment
2. Current and future antifungal therapy: New targets for antifungal agents
3. Animal models: Usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis
4. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones
5. Aspergillosis
6. Fungal infections in patients with acute leukemia
7. Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases
8. Antifungal dynamics of LY-303366, an investigational echinocandin B analog, against Candida spp.
9. In vitro activity of new oral triazole, BMS-207147 (ER-30346)
10. Combination therapy in experimental invasive aspergillosis
11. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis
12. New antifungal agents
13. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191
14. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis
15. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum
16. Aspergillosis complicating neoplastic disease
17. In vitro activity of the echinocandin antifungal agent LY-303366 in comparison with itraconazole and amphotericin B against Aspergillus spp.
18. Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis
19. Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis
20. The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis
21. Saperconazole therapy in a rabbit model of invasive aspergillosis
22. Efficacy of fluconazole in experimental invasive aspergillosis
23. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes
24. Effect of immunosuppression and amphotericin B on aspergillus antigen in an experimental model
25. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY-303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits
26. In vitro activity of two echinocandin derivatives, LY-303366 and MK-0991 (L-763,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi
27. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, SCH 56592, and voriconazole
28. The diagnosis of invasive aspergillosis by enzyme-linked immunosorbent assay for circulating antigen